No Data
No Data
Novartis Says Longer-Term Data Highlight Kisqali's Efficacy as Early Breast Cancer Treatment
Deutsche Bank Sticks to Their Hold Rating for Novartis AG (NOVN)
Novartis Announces Positive Results From Late-Stage Study on Fabhalta
On Saturday, Novartis Announced Longer-term Results From Phase 3 ASC4FIRST Trial Of Scemblix (Asciminib) Compared To Standard-Of-Care Tyrosine Kinase Inhibitors And Imatinib Alone In Adult Patients With Newly Diagnosed Chronic Myeloid Leukemia
Top Gap Ups and Downs on Friday: CNQ, EQNR, LULU and More
Novartis Touts Encouraging Data From Late-Stage Study For Fabhalta In Rare Type Of Blood Disorder
No Data
103827296 : Halo Medan hai hai English understand I'm sorry
72627089 : fractional shares
72627089 : would like to chat about fractional shares
(R-long)103834298 : stop all
l0lBElBgG : k